Literature DB >> 32044355

Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1.

Wei Du1, David Machalz2, Qi Yan1, Erik J Sorensen3, Gerhard Wolber4, Matthias Bureik5.   

Abstract

The human cytochrome P450 enzyme CYP4Z1 remains an understudied enzyme despite its association with poor prognosis and overexpression in breast cancer. Hence, CYP4Z1 has previously been suggested as an anti-breast cancer target. In the present study we employed extended mutation analysis to increase our understanding of the substrate binding mode of this enzyme. In a combined in vitro and in silico approach we show for the first time that residue Arg487 plays an important role in substrate recognition and binding of CYP4Z1. Using a large array of recombinant CYP4Z1 mutants we show that, apart from Asn381, all other postulated binding residues only play an auxiliary role in substrate recognition and binding. Different substrate interaction motifs were identified via dynamic pharmacophores (dynophores) and their impact on catalytically competent substrate binding was classified. These new insights on the substrate recognition and binding mode represent an important step towards the rational design of CYP4Z1 prodrugs and guide further investigations into the so far poorly understood physiological role of CYP4Z1.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; CYP4Z1; Molecular modeling; Mutational studies; Substrate recognition

Year:  2020        PMID: 32044355     DOI: 10.1016/j.bcp.2020.113850

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  New Proluciferin Substrates for Human CYP4 Family Enzymes.

Authors:  Jingyao Liu; David Machalz; Gerhard Wolber; Erik J Sorensen; Matthias Bureik
Journal:  Appl Biochem Biotechnol       Date:  2020-09-01       Impact factor: 2.926

2.  Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors.

Authors:  Katrin Denzinger; Trung Ngoc Nguyen; Theresa Noonan; Gerhard Wolber; Marcel Bermudez
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

3.  Cytochrome 4Z1 Expression Is Correlated with Poor Prognosis in Patients with Cervical Cancer.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Yahya M Al-Sarayra; Renata A Al-Saraireh; Ghadeer H Al-Muhaisen; Yanal S Al-Mahdy; Ahlam M Al-Kharabsheh; Seham M Abufraijeh; Hamzeh Mohammad Alrawashdeh
Journal:  Curr Oncol       Date:  2021-09-16       Impact factor: 3.677

4.  Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Ahmed M M Youssef; Sameeh Al-Sarayreh; Ghadeer H Almuhaisen; Nedal Alnawaiseh; Jehad M Al-Shuneigat; Hamzeh M Alrawashdeh
Journal:  Onco Targets Ther       Date:  2021-11-12       Impact factor: 4.147

5.  A convenient test system for the identification of CYP4V2 inhibitors.

Authors:  Shishir Sharma; Sijie Liu; Pradeepraj Durairaj; David Machalz; Gerhard Wolber; Matthias Bureik
Journal:  Mol Vis       Date:  2021-10-06       Impact factor: 2.367

6.  Cytochrome 4Z1 Expression Connotes Unfavorable Prognosis in Ovarian Cancers.

Authors:  Yousef M Al-Saraireh; Fatemah O F O Alshammari; Anas O Satari; Yanal S Al-Mahdy; Ghadeer H Almuhaisen; Omar H Abu-Azzam; Ala N Uwais; Seham M Abufraijeh; Ahlam M Al-Kharabsheh; Sa'ed M Al-Dalain; Aiman Al-Qtaitat; Fatima Al-Tarawneh; Jehad M Al Shuneigat; Sameeh A Al-Sarayreh
Journal:  Medicina (Kaunas)       Date:  2022-09-13       Impact factor: 2.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.